Bio-Technology General Euflexxa 1% Sodium Hyaluronate

Valsts: Singapūra

Valoda: angļu

Klimata pārmaiņas: HSA (Health Sciences Authority)

Pieejams no:

FERRING PHARMACEUTICALS PRIVATE LIMITED

Klase:

Class D medical device

Ražojis:

Bio-Technology General (Israel) Ltd.

Ārstniecības joma:

Orthopaedics

Ārstēšanas norādes:

EUFLEXXA is indicated for the treatment of pain caused by osteoarthritis of the knee, hip, temporomandibular, carpometacarpal, shoulder and ankle joints. EUFLEXXA aids in lubrication of the joint, allows for greater mobility and flexibility of the treated joint, and reduces pain in the affected joint.

Produktu pārskats:

Device System Info:[Sterile Medical Device], EUFLEXXA is packed in a single-use, aseptically-filled disposable sterile 2.25 ml syringe (nominal volume) containing either 1 ml or 2 ml of 1% microbial fermentation-derived NaHA in phosphate-buffered saline; Models: Euflexxa 1% Sodium Hyaluronate - 3 x 2ml, Euflexxa 1% Sodium Hyaluronate - 1 x 2ml

Autorizācija datums:

2017-04-28